Business Context and Reporting Period
Company: BridgeBio Pharma, Inc. (BBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: March 29, 2021
Event: Item 8.01 - Other Events (License and Collaboration Agreement)
Key Financial Metrics and Transaction Terms
This filing details a strategic partnership rather than periodic financial results. Key financial terms of the agreement include:
- Total Potential Payments: Up to approximately $2.45 billion in aggregate.
- Upfront and Milestone Payments: Over $100.0 million in upfront, regulatory, and launch milestone payments.
- Commercial Milestones: Remainder of potential payments subject to achievement of specified commercial milestones.
- Royalties: Tiered royalties in the high teens percentage of adjusted net sales (outside U.S. and Greater China).
- Cost Sharing: Global development costs shared at 40% (QED) and 60% (Helsinn).
- Profit Sharing: 50:50 basis for co-commercialization in the United States (subject to FDA approval).
Material Changes and Strategic Developments
On March 29, 2021, QED Therapeutics, Inc. (a subsidiary of BridgeBio) entered into an agreement with Helsinn Healthcare S.A. and Helsinn Therapeutics (U.S.), Inc. Key changes include:
- Licensing Rights: Helsinn received exclusive rights to develop, manufacture, and commercialize infigratinib in oncology and all other indications except achondroplasia or skeletal dysplasias.
- Geographic Scope: Worldwide, excluding the People's Republic of China, Hong Kong, and Macau ("Greater China").
- Co-Commercialization: QED retains a co-exclusive license to co-commercialize infigratinib in the United States for licensed indications.
- Conditions Precedent: Effectiveness is subject to specified conditions, including the expiration or early termination of the Hart-Scott-Rodino Antitrust waiting period.
Guidance, Outlook, and Risks
Outlook: The agreement positions the company to share development costs and potential commercial profits for infigratinib in the U.S. market while monetizing global rights outside the U.S. and Greater China.
Risks and Contingencies:
- Regulatory Approval: U.S. co-commercialization is subject to FDA approval.
- Antitrust Review: The transaction is contingent on the expiration or early termination of the Hart-Scott-Rodino waiting period.
- Milestone Achievement: The majority of the $2.45 billion potential value is contingent on achieving future commercial milestones.
Investor Verification Checklist
- Verify the status of the Hart-Scott-Rodino Antitrust waiting period to confirm transaction effectiveness.
- Confirm the specific definitions of "adjusted net sales" and the exact royalty tiers in the high teens.
- Monitor FDA regulatory progress for infigratinib in oncology indications to assess U.S. co-commercialization viability.
- Review future filings for the timing and receipt of the initial $100+ million in upfront and regulatory payments.